DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer & Director Scott Kellen - Chief Financial Officer & Company Secretary Lorianne Masuoka - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics Third Quarter 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________ Commission File Number: 001-36291 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) ...

Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results Conference Call and Webcast Thursday November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time ● Implemented Updates to AIS Program Intended to Enhance Probability of Trial Success and Expedite Study Completion, with Potential for a Reduced Study Size ● Preeclampsia Phase 2 Trial Received Regulatory Approval and First Patient Dosed ● Cash Runway Into Q3 2026 Minneapolis, Minnesota – November 13 ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 14th: IAMGOLD Corporation (IAG) : This intermediate gold producer has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 30.8% over the last 60 days. IAMGOLD' shares gained 17.2% over the last three months compared with the S&P 500's advance of 3.2%. The company possesses a Momentum Score of A. DiaMedica Therapeutics Inc. (DMAC) : This clinical sta ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer & Director Lorianne Masuoka - Chief Medical Officer Scott Kellen - Chief Financial Officer & Company Secretary Conference Call Participants Thomas Flaten - Lake Street Operator Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics Second Quarter 2024 Conference Call. An audio recording of the webcast will be available ...

Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results Conference Call and Webcast August 8 at 8:00 AM Eastern Time / 7:00 AM Central Time ● Acute Ischemic Stroke (AIS) Phase 2/3 ReMEDy2 Trial Interim Enrollment (n=144) Targeted for Q1 2025 ● Preeclampsia Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 with Proof-of-Concept Results Targeted for First Half 2025 ● Completed $12 Million Private Placement, Extending Cash Runway Into Q3 2026 M ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________ Commission File Number: 001-36291 ____________________ DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. DiaMedica Therapeutics, Inc. (DMAC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out. DiaMedica Therapeutics, Inc. is one of 1023 individual stocks in the Medical sector. Collectively, these companies sit at #5 ...

DiaMedica Therapeutics (NASDAQ:DMAC) is expected to complete enrollment for an interim futility analysis of its phase 2/3 ReMEDy2 clinical trial, using DM199 for the treatment of patients with acute ischemic stroke [AIS]. Enrollment of 144 patients for such an analysis is expected by Q1 of 2025, barring that there are no delays in recruitment. Having said that, this sets up a chance for it to target a very large multibillion-dollar market, where there are no FDA approved therapies. The company is in the pro ...

| --- | |-------------------------------------------------------------------------------------------------| | | | Rick Pauls - President, CEO & Director Lorianne Masuoka - Chief Medical Officer | | Scott Kellen - CFO & Company Secretary | | Conference Call Participants | | Chase Knickerbocker - Craig-Hallum Thomas Flaten - Lake Street François Brisebois - Oppenheimer | An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor ...